Nanologica presents at Erik Penser Bank Healthcare day on Feb 24
21 February, 2022
CEO Andreas Bhagwani will present at 14.20 and the presentation can be followed on this link. Nanologica’s presentation starts at 5:21:30.
Latest news
Categories
News archive
CEO Comment Q4 2021
9 February, 2022
AN EXCITING TIME AHEAD During the year, major changes have been made in the company’s two business areas; in Chromatography, Nanologica now focuses mainly on preparative chromatography, and in Drug Development the strategy has been refined to focus on inhaled drugs and respiratory diseases. This has been done to create the best possible growth conditions and value development going forward, for each business area as well as for the company as a whole. In line
Nanologica’s Year-End Report 2021
8 February, 2022
FINANCIAL SUMMARY Net sales for the fourth quarter amounted to TSEK 676 (6,071) and for the full year to TSEK 12,914 (16,135) The operating result for the fourth quarter amounted to TSEK -14,108 (-3,648) and for the full year to TSEK -40,689 (-19,571) Result after tax for the fourth quarter amounted to TSEK -15,222 (-5,427) and for the full year to TSEK -44,829 (-22,199) Earnings per share before and after dilution were SEK -0,54 (-0,20)
Nanologicas bokslutskommuniké 2021
8 February, 2022
FINANSIELL SAMMANFATTNING Nettoomsättningen för fjärde kvartalet uppgick till 676 TSEK (6 071) och för helåret till 12 914 TSEK (16 135) Rörelseresultatet för kvartalet uppgick till -14 108 TSEK (-3 648) och för helåret till -40 689 TSEK (-19 571) Resultatet efter skatt för kvartalet uppgick till -15 222 TSEK (-5 427) och för helåret till -44 829 TSEK (-22 199) Resultat per aktie före och efter utspädning var -0,54 SEK (-0,20) för kvartalet och